Merck & Co. said on Sept. 4 that the Food and Drug Administration approved what Merck said was a groundbreaking cancer treatment that it hopes will cure many patients and generate billions of dollars in revenue. On the same day, Bristol-Myers Squibb said bunk to that, alleging patent infringement in a lawsuit in federal court in Delaware, where both global pharmaceutical giants are registered.